Our Financial Highlights for 2021
The Group delivered a strong operational and financial performance in 2021, leaving it well placed to take advantage of further growth opportunities in 2022.
- Strong overall revenue growth driven by Consumer Healthcare, underpinned by continued market penetration via e-commerce activity, which now represents around 25% of Group sales
- Consumer Healthcare see-through revenue* up 31% to £121.8m (2020: £93.0m) and up 36% at constant exchange rates* (CER) with excellent performance from Kelo-cote and the inclusion of Amberen, acquired in December 2020
- Robust Prescription Medicines performance with revenues up 8% to £47.8m (2020: £44.5m), with strong H2 recovery as the effects of COVID-19 receded
To view in detail click here to download our 2021 Annual Report
|Year ended 31 December 2017 £m||Year ended 31 December 2018 £m||Year ended 31 December 2019 £m||Year ended 31 December 2020 £m||Year ended 31 December 2021 £m|
|Operating profit before non-underlying items||25.8||28.9||37.4||36.8||45.6|
|Non-underlying operating items||4.4||(5.3)||(1.8)||(20.5)||(24.0)|
|Profit before tax before non-underlying items||23.9||28.1||32.9||33.5||42.2|
|Profit before tax after non-underlying items||28.3||22.8||31.1||13.0||18.2|
|Average shares in issue (millions)||473.8||497.2||520.7||531.1||535.3|
|Shares in issue at period end (millions)||475.0||518.2||529.4||532.9||538.2|
|Earnings per share – basic (p)||6.08||3.69||4.80||1.51||1.37|
|Earnings per share – adjusted underlying basic (p)||4.05||4.54||5.09||5.11||6.39|
* Non-IFRS alternative performance measures (see note 33). See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.